Percentage of students who play sports together with family every day, most days or about once a week, by country, gender and age

<p><b>Copyright information:</b></p><p>Taken from "Family joint activities in a cross-national perspective"</p><p>http://www.biomedcentral.com/1471-2458/7/94</p><p>BMC Public Health 2007;7():94-94.</p><p>Published online 30 May 2007</p><p>PMCID:PMC1904207.</p><p></p

Clarithromycin resistance molecular mechanisms, clarithromycin susceptibility testing and subspecies identification of <i>M</i>. <i>abscessus</i> complex strains.

<p>^a ND, Not determined</p><p>^b nt, Nucleotide</p><p>^c Wt, Wild type</p><p>^d D, days</p><p>^e MIC values in μg/mL</p><p>^f MIC ranges for microdilution broth: ≤ 2, Susceptible; ≥ 8, Resistant</p><p>^g MIC ranges for E-test: ≤ 1, Susceptible; ≥ 4, Resistant</p><p>^h The hyphen indicates that phenotypic techniques were not performed due to strain non-recovery.</p><p>ⁱ Double peak in DNA sequence</p><p>Clarithromycin resistance molecular mechanisms, clarithromycin susceptibility testing and subspecies identification of <i>M</i>. <i>abscessus</i> complex strains.</p

Comparison between <i>Mycobacterium abscessus</i> subsp. <i>bolletii</i> 07I004 strain and <i>Mycobacterium</i> abscessus complex reference strains.

<p>^a Values shown in bold indicate the highest percentage of identity</p><p>^b<i>M</i>. <i>abscessus</i> subsp. <i>bolletii</i> CCGU 50184 used for <i>rpoB</i> and <i>secA1</i> genes.</p><p>^c<i>M</i>. <i>abscessus</i> subsp. <i>bolletii</i> CIP 108541 used for <i>hsp65</i> and <i>sodA</i> genes.</p><p>Comparison between <i>Mycobacterium abscessus</i> subsp. <i>bolletii</i> 07I004 strain and <i>Mycobacterium</i> abscessus complex reference strains.</p

sj-pdf-1-ctj-10.1177_17407745221132302 – Supplemental material for Strategies to facilitate adolescent access to medicines: Improving regulatory guidance

Supplemental material, sj-pdf-1-ctj-10.1177_17407745221132302 for Strategies to facilitate adolescent access to medicines: Improving regulatory guidance by Christina Bucci-Rechtweg, Angeliki Siapkara, Kristina An Haack Bonnet, Solange Corriol Rohou, Elin Haf Davies, Martine Dehlinger Kremer, Margaret Gamalo, Carmen Moreno, Robert M Nelson and Rhian Thomas Turner in Clinical Trials</p

sj-pdf-2-ctj-10.1177_17407745221132302 – Supplemental material for Strategies to facilitate adolescent access to medicines: Improving regulatory guidance

Supplemental material, sj-pdf-2-ctj-10.1177_17407745221132302 for Strategies to facilitate adolescent access to medicines: Improving regulatory guidance by Christina Bucci-Rechtweg, Angeliki Siapkara, Kristina An Haack Bonnet, Solange Corriol Rohou, Elin Haf Davies, Martine Dehlinger Kremer, Margaret Gamalo, Carmen Moreno, Robert M Nelson and Rhian Thomas Turner in Clinical Trials</p

Relationship between CGAS score and TAS level at baseline and at two-year follow-up assessment.

<p>a) At baseline, there is a positive significant relationship between CGAS and TAS indicating that the better the patient's functioning, the higher his level of TAS; b) at one year and at two years of follow-up, this relationship is significantly reversed, with patients with the highest levels of TAS having the worst functionality.</p

Relationship between total antioxidant status (TAS) and Children's Global Assessment Scale (CGAS) scores over a two year follow-up.

<p>Relationship between total antioxidant status (TAS) and Children's Global Assessment Scale (CGAS) scores over a two year follow-up.</p

Sociodemographic characteristics and total antioxidant status (TAS).

<p>Sociodemographic characteristics and total antioxidant status (TAS).</p

Coefficients of linear regression models between clinical assessment and TAS level at each visit point.

<p>Coefficients of linear regression models between clinical assessment and TAS level at each visit point.</p

Effect size of CGAS on TAS (and 95% CIs).

<p>Effect size of CGAS on TAS (and 95% CIs).</p